focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiopharma Cred. Regulatory News (BPCR)

Share Price Information for Biopharma Cred. (BPCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.878
Bid: 0.876
Ask: 0.88
Change: 0.002 (0.23%)
Spread: 0.004 (0.457%)
Open: 0.88
High: 0.88
Low: 0.874
Prev. Close: 0.876
BPCR Live PriceLast checked at -
BioPharma Credit is an Investment Trust

To generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Full Year Results

1 Mar 2018 07:00

RNS Number : 3046G
BioPharma Credit PLC
01 March 2018
 

1 March 2018

 

BIOPHARMA CREDIT PLC

("The Company")

 

NOTICE OF RESULTS

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its audited Full Year Results for the period ending 31 December 2017, on Thursday 8 March 2018.

A management presentation will be held at 09:30 at Buchanan, 107 Cheapside, EC2V 6DN. A conference call facility will also be available.

To confirm your attendance, or request conference call details, RSVP to henryw@buchanan.uk.com.

 LEI: 213800AV55PYXAS7SY24

-Ends-

Enquiries

 

BioPharma Credit PLC

via Link Company Matters Limited

Company Secretary

+44 (0) 1392 477 500

 

Goldman Sachs International (Joint Bookrunner)

+44 (0)207 774 1000

Charlie Lytle

Shomick Bhattacharya / Jennie Holloway / Tom Hartley

 

J.P. Morgan Cazenove (Joint Bookrunner)

+44 (0)20 7742 4000

William Simmonds / Oliver Kenyon / Anne Ross

 

Buchanan

+44 (0)20 7466 5000

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

biopharmacredit@buchanan.uk.com

 

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORZMGZZNRVGRZM
Date   Source Headline
13th May 202411:40 amRNSDirector/PDMR Shareholding
10th May 20243:11 pmRNSSTATEMENT RE COHERUS BIOSCIENCES, INC.
8th May 20243:52 pmRNSHolding(s) in Company
7th May 20246:15 pmRNSTransaction in Own Shares
3rd May 20246:15 pmRNSTransaction in Own Shares
2nd May 20246:15 pmRNSTransaction in Own Shares
2nd May 202412:18 pmRNSNEW INVESTMENT OF UP TO US$400 MILLION
1st May 202410:25 amRNSTotal Voting Rights
30th Apr 20246:15 pmRNSTransaction in Own Shares
29th Apr 20246:15 pmRNSTransaction in Own Shares
26th Apr 20246:15 pmRNSTransaction in Own Shares
24th Apr 20246:15 pmRNSTransaction in Own Shares
24th Apr 20247:00 amRNSNEW INVESTMENT OF UP TO US$100 MILLION
23rd Apr 20246:15 pmRNSTransaction in Own Shares
22nd Apr 20246:15 pmRNSTransaction in Own Shares
22nd Apr 20244:00 pmRNSNet Asset Value(s) and Monthly Factsheet
19th Apr 20246:15 pmRNSTransaction in Own Shares
18th Apr 20246:15 pmRNSTransaction in Own Shares
18th Apr 20246:00 pmRNSNotice of AGM
17th Apr 20246:15 pmRNSTransaction in Own Shares
16th Apr 20246:15 pmRNSTransaction in Own Shares
15th Apr 20246:15 pmRNSTransaction in Own Shares
12th Apr 20246:15 pmRNSTransaction in Own Shares
11th Apr 20246:15 pmRNSTransaction in Own Shares
10th Apr 20246:15 pmRNSTransaction in Own Shares
9th Apr 20246:15 pmRNSTransaction in Own Shares
8th Apr 20246:15 pmRNSTransaction in Own Shares
4th Apr 20246:15 pmRNSTransaction in Own Shares
3rd Apr 20246:15 pmRNSTransaction in Own Shares
2nd Apr 20246:15 pmRNSTransaction in Own Shares
27th Mar 20244:48 pmRNSDirector/PDMR Shareholding
27th Mar 20247:01 amRNSUPDATES TO THE DISCOUNT CONTROL MECHANISM
27th Mar 20247:00 amRNSFINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
25th Mar 202411:35 amRNSDirector/PDMR Shareholding
21st Mar 20244:05 pmRNSDividend Declaration
21st Mar 20244:00 pmRNSNet Asset Value(s)
15th Mar 20244:35 pmRNSUPDATE ON INVESTMENT
11th Mar 20244:00 pmRNSNet Asset Value(s) and Monthly Factsheet
1st Mar 20243:10 pmRNSTotal Voting Rights
27th Feb 20247:00 amRNSNotice of Full Year Results
26th Feb 20246:15 pmRNSTransaction in Own Shares
20th Feb 20246:15 pmRNSTransaction in Own Shares
19th Feb 20246:15 pmRNSTransaction in Own Shares
16th Feb 20246:15 pmRNSTransaction in Own Shares
13th Feb 20246:15 pmRNSTransaction in Own Shares
13th Feb 20247:00 amRNSSTATEMENT RE IMMUNOGEN, INC.
9th Feb 20246:15 pmRNSTransaction in Own Shares
8th Feb 20246:15 pmRNSTransaction in Own Shares
8th Feb 20247:00 amRNSDividend Declaration
7th Feb 20246:15 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.